4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout...

Area of Science:

• Neuroscience
• Genetics
• Epilepsy Research

Background:

• Lafora disease (LD) is a rare, progressive myoclonic epilepsy linked to mutations in EPM2A (laforin) or EPM2B (malin).
• Malin knockout mice exhibit neurological symptoms and increased seizure susceptibility, modeling aspects of human LD.

Purpose of the Study:

• To investigate the neuroprotective effects of 4-phenylbutyric acid (4-PBA) and metformin in a malin knockout mouse model of Lafora disease.
• To assess the impact of these treatments on seizure response to pentylenetetrazol (PTZ).

Main Methods:

• Utilized malin knockout mice, a genetic model for Lafora disease.
• Administered 4-phenylbutyric acid (4-PBA) and metformin to the mice.
• Evaluated seizure susceptibility and mortality following pentylenetetrazol (PTZ) challenge.

Main Results:

• Both 4-PBA and metformin treatments significantly decreased seizure susceptibility in malin knockout mice.
• Seizure number and duration were reduced, and PTZ-induced mortality was eliminated.
• These findings corroborate previous observations of beneficial effects of these compounds in the LD model.

Conclusions:

• 4-phenylbutyric acid (4-PBA) and metformin demonstrate significant neuroprotective effects in a mouse model of Lafora disease.
• These drugs reduce hyperexcitability and improve outcomes in the context of PTZ-induced seizures.
• The study supports the therapeutic potential of 4-PBA and metformin for managing neurological complications in Lafora disease.